Recombinant Data Corp. Implements a Translational Research Solution at the University of Massachusetts Medical School
Originally published September 3, 2009
Recombinant Data Corp., a healthcare data warehousing and clinical intelligence solutions provider, recently announced that it has implemented a translational research solution at the University of Massachusetts Medical School.
The project, known as the Massachusetts Integrated Clinical Academic Research Database (MICARD), includes i2b2, an open source technology funded by the National Institutes of Health (NIH). i2b2 provides an Institutional Review Board (IRB)-compliant environment for managing and analyzing clinical data for population-based research, genomic research, clinical trials, and the development of new interventions and technologies. The solution empowers researchers through a simple self-service cohort selection interface to generate hypotheses using de-identified data from the Data Trust, Recombinant’s healthcare data warehouse solution.
The Recombinant Data Trust aggregates, cleanses and centrally manages patient information to enable integrated reporting across institutions while relieving pressure on transactional systems. It also provides system-wide governance mechanisms to control data security, privacy, and auditability.
“MICARD, as part of the Conquering Diseases Bio-Repository project, is a significant development in the field of translational research,” said Ralph Zottola, Associate CIO, UMass Medical School. “Clinical investigators were accustomed to waiting months for specific research data requests. Our implementation with Recombinant reduces this waiting period to minutes.”
This BeyeNETWORK news item contains information from a recent press release by the company mentioned.
Copyright 2004 — 2019. Powell Media, LLC. All rights reserved.
BeyeNETWORK™ is a trademark of Powell Media, LLC